ADULTS WITH CATEGORY 3 OR 4 PAIN ARE LIKELY TO:

Sources: NIH National Health Interview Survey, Institute of Medicine of the National Academies

OUR APPROACH

N-001 is a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures.

Pain is felt when sensory neurons transmit signals to the brain. Current treatments meant to disrupt pain signals from peripheral sensory neurons are not neuron-specific, and consequently suffer from a variety of off-target effects like addiction formation, inhibition of motor neurons, and destruction of the surrounding tissues.

As a superior alternative, Neurocarrus research and development aims to disrupt pain signals from sensory nerve cells via targeted delivery of bacterial proteins. Those proteins modify the neuron's skeleton to block signalling. Unlike other existing FDA approved proteins in the marketplace, N-001 affects just sensory nerves, and leaves motor nerves untouched.

OUR APPROACH

N-001 is a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures.

Pain is felt when sensory neurons transmit signals to the brain. Current treatments meant to disrupt pain signals from peripheral sensory neurons are not neuron-specific, and consequently suffer from a variety of off-target effects like addiction formation, inhibition of motor neurons, and destruction of the surrounding tissues.

As a superior alternative, Neurocarrus research and development aims to disrupt pain signals from sensory nerve cells via targeted delivery of bacterial proteins. Those proteins modify the neuron's skeleton to block signalling. Unlike other existing FDA approved proteins in the marketplace, N-001 affects just sensory nerves, and leaves motor nerves untouched.

ABOUT US

Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet need for a product that can safely and specifically disrupt peripheral sensory neurons. N-001 was engineered for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute pain, such as pain following surgery. N-001 is a leading technology in the fight against the opioid crisis, which claims the lives of tens of thousands of Americans each year. A safe, effective treatment for pain, which results in a disease burden of over $635 billion in the US alone, would have a major impact on human health through increased mobility and generally improved life quality. With N-001, we hope to accomplish this without systemic side effects like nausea, dizziness, and addiction.

Headquartered in Lincoln, Nebraska, Neurocarrus was founded by prominent research scientists in the field of protein engineering, and is led by a strong management team with expertise in business, biotechnology and medicine. Since inception, the company has generated extensive in vitro and in vivo data supporting the efficacy of N-001.

* Institute of Medicine of the National Academies. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. (2012)